AB Science receives FDA and EMA authorization for phase 3 Trial of prostate cancer treatment
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
These medicines are essential in preventing RhD immunisation during pregnancy
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
The facility will manufacture 13,200 MTPA Benzyl Chloride, 9,600 MTPA Benzyl Alcohol, and 7,200 MTPA Benzaldehyde
Surpassing 1,000 Company Owned Company Operated stores
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Subscribe To Our Newsletter & Stay Updated